Prospects for AbbVie Inc.’s Venclexta (venetoclax) becoming a fully approved treatment for acute myeloid leukemia (AML) were thrown into doubt when the B-cell lymphoma-2 inhibitor failed to show a significant improvement in the primary endpoint of overall survival (OS) in the ongoing VIALE-C Phase III study, although it did demonstrate numerical improvement.
AbbVie on 28 February said that the VIALE-C trial evaluating Venclexta in combination with low-dose cytarabine (LDAC) versus LDAC in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?